Navigation Links
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome

ting pain as measured by the Patient Experience Diary (PED), the overall impression of patient well being as measured by the Patient Global Impression of Change (PGIC) and an analysis of physical function as measured by the SF-36 Physical Component Summary for patients receiving either dose of milnacipran compared to placebo. The difference between active doses and placebo was assessed by a responder analysis with a responder defined as a subject meeting the criteria for the treatment of pain associated with fibromyalgia and in addition showing improvement in physical function as assessed by the SF-36 Physical Component Summary.

Treatment of Pain Associated with Fibromyalgia

This endpoint showed statistically significant improvement for milnacipran compared to placebo for patients receiving 200 mg per day of milnacipran (p=0.004) and for patients receiving 100 mg per day of milnacipran (p=0.025).

These results were analyzed using the Baseline Observation Carried Forward (BOCF) analysis, as agreed to with the U.S. Food and Drug Administration (FDA).

Treatment of Fibromyalgia Syndrome

This endpoint also showed statistically significant improvement for milnacipran compared to placebo for both the 200mg per day dose (p=0.015) and 100mg per day dose (p=0.011) using the Baseline Observation Carried Forward (BOCF) analysis. Results for both endpoints listed above were also statistically significant when analyzed using a Last Observation Carried Forward (LOCF) method.

Component Assessments

In addition, when analyzed according to the pre-specified analysis plan both the pain and the PGIC components of the composite endpoint individually achieved statistical significance in favor of milnacipran at both doses and the SF-36 Physical Component Summary met statistical significance at one dose.

Tolerability

Milnacipran was generally well tolerated, with the majority of patient withdrawals occurring early in the trial.
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
2. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:11/21/2014)... 21, 2014  World Hemp Oil, an importer of ... they are now offering legal, organic oil with high ... strains grown in medical marijuana states. People suffering from ... as Parkinson,s, MS, and spinal cord injury, no longer ... because imported CBD Oil Is legal in all states. ...
(Date:11/21/2014)... , Nov. 21, 2014 ... European Medicines Agency (EMA) has granted Orphan ... lead product candidate, for the treatment of ... rare, severely disabling genetic disease characterized by ... (flare-ups) and new abnormal bone formation. This ...
(Date:11/21/2014)... BRYDGES, Ontario , Nov. 20, 2014 /PRNewswire/ ... monitor mounting solutions and reading room environment guidance, ... their newest musculoskeletal radiology reading room, which may ... room designs at Penn Medicine. ... by the American College of Radiology,s Imaging 3.0 ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3
... Jan. 2 Amicus Therapeutics,Inc. (Nasdaq: FOLD ), ... Officer, will present a corporate update at the 26th ... January 7,2008 at 11:30 am (Pacific Standard Time) at ... be webcast live and may be accessed by visiting,Amicus, ...
... Inc. (Nasdaq: ALTH ) today announced that ... pre-specified 65-patient,safety review of data from the Company,s ... patients with relapsed or refractory peripheral,T-cell lymphoma (PTCL), ... the,protocol. This interim assessment was based upon an ...
Cached Medicine Technology:Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference 2Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 2Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 4Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 5
(Date:11/22/2014)... (PRWEB) November 23, 2014 Recently, ... has introduced a new promotion of mag locks for ... provided an attracting discount on these fresh products. Customers ... mag locks for glass doors are in excellent performance. ... browse the website as soon as possible. They ...
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand in wedding dresses, ... business offers a wide range of special occasion dresses, ... them to create multiple looks easily. , According to ... of chic wedding dresses has been prepared for many ... rates now. Dylan Queen can always create what ladies ...
(Date:11/22/2014)... “Due to my knee replacement surgery, I had to use ... the ice grip attachment, I noticed how dangerous the unprotected ... a safer way to prevent possible injuries, so I invented ... offers added safety and stability in slick and icy conditions. ... damage associated with traditional spiked ice grips. As a result, ...
(Date:11/22/2014)... November 22, 2014 In order to provide ... promotion of cocktail party dresses. The business knows that a ... social occasions. , Now, the party dresses supplier’s ... 70% off. As the leading company in fashion industry, LunaDress ... outfit for every customer. So it always raises the professional ...
(Date:11/22/2014)... "My friend went in for a ... machine," said an inventor from Cambria Heights, N.Y. "To ... a second time because the first results were inaccurate. ... the patent-pending MAMO EASY to offer a more comfortable ... the patient from the pain normally involved with this ...
Breaking Medicine News(10 mins):Health News:Discounted Mag Locks for Glass Doors Revealed by Locks-Magnetic.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2
... to Attend Conference, LAS VEGAS, Sept. 10 ... http://www.skinvisible.com ), the developers,of Invisicare(R), a proprietary ... announced that Mr. Terry Howlett,President & CEO, will ... & Co.,Investor Summit on September 18, 2007 at ...
... Montague and Wolf Haldenstein Obtain Third-Largest Settlement,in Securities ... PHILADELPHIA, Sept. 10 Judge Morris E.,Lasker ... of Massachusetts has,granted final approval of a $52.5 ... actions against Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: ...
... a protein best known as a common marker of inflammation ... The research, published by Cell Press in the September issue ... a potential target for cancer treatment. , CRP is a ... during the process of inflammation in response to the inflammatory ...
... eating fattening foods and not getting enough exercise are all ... disease more so if you have a family history. ... women dont change these habits as often as men, even ... reporting in the September issue of the American Heart ...
... Expansion of Services Now Ranges From Birth Through ... The Exceptional,Children,s Foundation (ECF) announced today that it ... one of California,s largest and most,unique nonprofit organizations ... disabilities. As a result of the,merger, ECF becomes ...
... Abbott (NYSE:,ABT) -- the global health care company ... Index and the Dow Jones Sustainability North America,Index ... Abbott,s,continued leadership in business, environmental and social performance. ... approach to business," said,Miles D. White, chairman and ...
Cached Medicine News:Health News:Skinvisible to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007 2Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:Human C-reactive protein regulates myeloma tumor cell growth and survival 2Health News:Women less likely than men to change habits that increase heart disease risk 2Health News:Exceptional Children's Foundation Merger with Kayne Eras Center Creates One of State's Most Comprehensive Nonprofits Serving the Disabled 2Health News:Exceptional Children's Foundation Merger with Kayne Eras Center Creates One of State's Most Comprehensive Nonprofits Serving the Disabled 3Health News:Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance 2
... Available As One Unit, Shaped Like A Fan, ... Of A Phaco Incision. The Gauges Start At ... Up To With 100-Micron Increments. The ... Information As To The Preoperative And Postoperative Incision ...
... Unique Reversible Speculums Designed To ... By Flipping The Speculums Over, Allowing ... Palpebral Fissures To The Widest Possible ... Providing Unobstructed Around-The-Clock Access To The ...
... A Micrometer Handle, Designed To Dial An ... Single Footplate Allows Maximum Visibility, With Titanium ... Blade Tracks Better In Tissue, And Can ... Making A Paracentesis., ,Reusable, Autoclaveable, Made In The ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Medicine Products: